For US Healthcare Professionals

You are now leaving nmosdsymptoms.com

Horizon is not responsible for the content of external websites linked within nmosdsymptoms.com. Do you want to continue?
Woman using walker in a clinical setting, with text reading "Just because she isn't suffering an attack doesn't mean she isn't suffering" Woman using walker in a clinical setting, with text reading "Just because she isn't suffering an attack doesn't mean she isn't suffering"

Is it time to act? Your NMOSD patients may be revealing new or worsening disease activity like pain, vision changes, or bladder/bowel symptoms or have difficulty with dosing regimens.1,2

If you hear these cries for help, it may be time to intervene.

NMOSD management should include:

Long-term efficacy icon

Evaluating the long-term

efficacy of therapy2

Disease impact icon

Assessing the ongoing

impact of the disease1,2

Shield with an checkmark icon

Treatment decisions that

involve more than attack

reduction alone3,4

Support

Explore NMOSD resources

Support for Your Patients
Stay Up to Date

Receive the latest information about NMOSD

Sign Up Now

NMOSD, neuromyelitis optica spectrum disorder.

References
  • 1.

    Eaneff S, Wang V, Hanger M, et al. Patient perspectives on neuromyelitis optica spectrum disorders: data from the PatientsLikeMe online community. Mult Scler Relat Disord. 2017;17:116-122.

  • 2.

    Paul F, Marignier R, Palace J, et al. International Delphi Consensus on the management of AQP4· lgG+ NMOSD: recommendations for eculizumab, inebilizumab, and satralizumab. Neurol Neuroimmunol Neuroinflamm. 2023;10(4):e200124. doi: 10.1212/NXl.0000000000200124

  • 3.

    Held F, Klein A-K, Berthele A. Drug treatment of neuromyelitis optica spectrum disorders: out with the old, in with the new? Immunotargets Ther. 2021;10:87-101

  • 4.

    Wingerchuk DM, Lucchinetti CF. Neuromyelitis optica spectrum disorder. N Engl J Med. 2022;387:631-639. doi:10.1056/NEJMra1904655